Anthony A Fossa

Summary

Affiliation: Pfizer Global Research and Development
Country: USA

Publications

  1. ncbi Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig
    Anthony A Fossa
    Pfizer Global Research and Development, Department of Translational and Molecular Medicine, Groton, Connecticut 06340, USA
    Am J Trop Med Hyg 77:929-38. 2007
  2. ncbi Analyses of dynamic beat-to-beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol
    Anthony A Fossa
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Ann Noninvasive Electrocardiol 12:338-48. 2007
  3. ncbi QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization
    Anthony A Fossa
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Exp Ther 316:498-506. 2006
  4. ncbi Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants
    Anthony A Fossa
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 55:78-85. 2007
  5. ncbi Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig
    Anthony A Fossa
    Pfizer Global Research and Development, Eastern Point Rd, Bldg 118, MS 4036 Groton, CT 06340, USA
    Eur J Pharmacol 486:209-21. 2004
  6. ncbi Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition
    Anthony A Fossa
    Pfizer Global Research and Development, Eastern Point Rd, Bldg 118, MS 4036, Groton, CT 06340, USA
    J Pharmacol Exp Ther 312:1-11. 2005
  7. ncbi Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability
    Todd Wisialowski
    Pfizer Global Research and Development, Eastern Point Rd, Building 274, Groton, CT 06340, USA
    J Pharmacol Exp Ther 318:352-9. 2006
  8. ncbi The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment
    Anthony A Fossa
    Pfizer Global Research and Development, Eastern Point Road, Building 118, MS 4036, Groton, CT 06340, USA
    J Pharmacol Exp Ther 302:828-33. 2002
  9. ncbi Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine
    Anthony A Fossa
    Department of Global Safety Pharmacology, Department of Pharmacokinetics, Dynamics and Metabolism, and Neuroscience, Pfizer Global Research and Development Eastern Point Road, Groton, CT 06340, USA Electronic address
    Toxicol Appl Pharmacol 264:343-50. 2012
  10. ncbi Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1)
    W Ross Tracey
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Cardiovasc Drug Rev 21:17-32. 2003

Detail Information

Publications13

  1. ncbi Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig
    Anthony A Fossa
    Pfizer Global Research and Development, Department of Translational and Molecular Medicine, Groton, Connecticut 06340, USA
    Am J Trop Med Hyg 77:929-38. 2007
    ..Azithromycin alone and in combination with chloroquine showed no increase in alternans beyond vehicle baseline responses indicating no additional arrhythmia liability...
  2. ncbi Analyses of dynamic beat-to-beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of torsades de pointes during QT prolongation caused by sotalol
    Anthony A Fossa
    Pfizer Global Research and Development, Groton, Connecticut 06340, USA
    Ann Noninvasive Electrocardiol 12:338-48. 2007
    ..We examined whether analyses of sequential beat-to-beat QT and TQ interval measures can be used to quantify ECG restitution changes under normal sinus rhythm...
  3. ncbi QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization
    Anthony A Fossa
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Exp Ther 316:498-506. 2006
    ..Thus, dynamic beat-to-beat measurements of restitution could lead to clinically applicable ECG obtained biomarkers for assessment of changes associated with arrhythmogenic risk...
  4. ncbi Electrical alternans and hemodynamics in the anesthetized guinea pig can discriminate the cardiac safety of antidepressants
    Anthony A Fossa
    Pfizer Global Research and Development, Groton, CT 06340, USA
    J Pharmacol Toxicol Methods 55:78-85. 2007
    ..The arrhythmogenic risk of fluoxetine, citalopram, and venlafaxine were evaluated through preclinical assays measuring hERG, blood pressure and electrical alternans over their respective clinical unbound concentration ranges...
  5. ncbi Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig
    Anthony A Fossa
    Pfizer Global Research and Development, Eastern Point Rd, Bldg 118, MS 4036 Groton, CT 06340, USA
    Eur J Pharmacol 486:209-21. 2004
    ..The magnitude of effect on rate-dependent alternans may allow the differentiation of proarrhythmia and non-arrhythmic HERG blockers at clinically relevant concentrations...
  6. ncbi Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition
    Anthony A Fossa
    Pfizer Global Research and Development, Eastern Point Rd, Bldg 118, MS 4036, Groton, CT 06340, USA
    J Pharmacol Exp Ther 312:1-11. 2005
    ....
  7. ncbi Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability
    Todd Wisialowski
    Pfizer Global Research and Development, Eastern Point Rd, Building 274, Groton, CT 06340, USA
    J Pharmacol Exp Ther 318:352-9. 2006
    ..9 microM). The relative risk at therapeutic concentrations is erythromycin>moxifloxacin>telithromycin and appears to be consistent with clinical observations of torsade de pointes in patients...
  8. ncbi The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment
    Anthony A Fossa
    Pfizer Global Research and Development, Eastern Point Road, Building 118, MS 4036, Groton, CT 06340, USA
    J Pharmacol Exp Ther 302:828-33. 2002
    ..Inspection of the beat-to-beat QT-RR interval relationship in an individual animal can increase the sensitivity for more accurate clinical prediction...
  9. ncbi Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine
    Anthony A Fossa
    Department of Global Safety Pharmacology, Department of Pharmacokinetics, Dynamics and Metabolism, and Neuroscience, Pfizer Global Research and Development Eastern Point Road, Groton, CT 06340, USA Electronic address
    Toxicol Appl Pharmacol 264:343-50. 2012
    ..safety compared to acute NRI treatment...
  10. ncbi Zoniporide: a potent and selective inhibitor of the human sodium-hydrogen exchanger isoform 1 (NHE-1)
    W Ross Tracey
    Pfizer Global Research and Development, Groton, CT 06340, USA
    Cardiovasc Drug Rev 21:17-32. 2003
    ..Zoniporide represents a novel class of potent and selective human NHE-1 inhibitors with potential utility for providing cardioprotection in a clinical setting...
  11. ncbi The impact of drug-induced QT interval prolongation on drug discovery and development
    Bernard Fermini
    Pfizer Global Research and Development, Eastern Point Road MS 4083, Groton, Connecticut 06340, USA
    Nat Rev Drug Discov 2:439-47. 2003
    ....
  12. ncbi Assessing QT prolongation in conscious dogs: validation of a beat-to-beat method
    Anthony A Fossa
    iCardiac Technologies, Inc, 150 Allens Creek Road, Rochester, NY 14618, United States
    Pharmacol Ther 118:231-8. 2008
    ..However, some caveats based on observations may need to be considered due to inherent differences in QT intervals and sinus arrhythmia between canines and humans...
  13. ncbi Points to consider emerging from a mini-workshop on cardiac safety: assessing torsades de pointes liability
    Alan Bass
    Investigational and Regulatory Safety Pharmacology, Schering Plough Research Institute, 2015 Galloping Hill Road, Kenilworth, NJ 07033 0539, USA
    J Pharmacol Toxicol Methods 56:91-4. 2007
    ....